University of Nebraska Medical Center

DigitalCommons@UNMC
Journal Articles: Epidemiology

Epidemiology

2022

Disparities in Awareness of and Willingness to Participate in
Cancer Clinical Trials Between African American and White
Cancer Survivors
Gaurav Kumar
Jungyoon Kim
Paraskevi A. Farazi
Hongmei Wang
Dejun Su

Follow this and additional works at: https://digitalcommons.unmc.edu/coph_epidem_articles
Part of the Epidemiology Commons

(2022) 22:983
Kumar et al. BMC Cancer
https://doi.org/10.1186/s12885-022-10082-9

Open Access

RESEARCH

Disparities in awareness of and willingness
to participate in cancer clinical trials
between African American and White cancer
survivors
Gaurav Kumar1, Jungyoon Kim2, Paraskevi A. Farazi3, Hongmei Wang2 and Dejun Su1*

Abstract
Background: Cancer clinical trials (CCTs) are essential for cancer care, yet the evidence is scarce when it comes to
racial disparities in CCT participation among cancer survivors in the Midwest. This study aimed to 1) assess disparities
in the awareness of and willingness to participate in CCTs between African American and White cancer survivors; and
2) compare perceptions about CCTs between the two racial groups.
Methods: The study was based on cross-sectional data from the survey “Minority Patient Participation in Cancer
Clinical Trials” that collected information from 147 Black and White cancer survivors from Nebraska between 2015 and
2016. Chi-square tests and logistic regressions were used to assess differences between Black and White cancer survivors regarding their awareness, willingness, and perceptions associated with CCT participation.
Results: After adjusting for the effects of socio-demographic, health status, and psychosocial variables, Black cancer
survivors were much less likely than White cancer survivors to be aware of CCTs (AOR 0.26; CI 0.08–0.81), to express
willingness to participate in CCTs (AOR 0.03; CI 0.01, 0.32) and to actually participate in CCTs (AOR 0.13; CI 0.04–0.38).
Black cancer survivors reported a lower level of trust in physicians and were less likely than White cancer survivors to
believe that CCTs make a significant contribution to science.
Conclusions: Relative to White cancer survivors, Black cancer survivors had much lower awareness of and willingness
to participate in CCTs. Part of these differences might be related to the differential perception of CCTs, psychosocial
factors, and trust in physicians between the two groups.
Keywords: Cancer clinical trial, Cancer survivors, Awareness, Willingness, Perception, Racial disparity
Introduction
Cancer clinical trials (CCTs) are crucial for developing and testing new treatments for cancer patients.
However, only 3 to 5% of eligible adult cancer patients
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participate in clinical trials, even though most Americans (70%) view clinical trial participation favorably
[1, 2]. Low enrollment in CCT delay cancer research
advancement and increases the costs of developing and
disseminating effective cancer treatments [3, 4]. In the
United States (US), racial and ethnic minorities bear
a disproportionate burden of cancer morbidity and
mortality relative to non-Hispanic Whites [5, 6]. Less
than 2% of the National Cancer Institute (NCI) sponsored clinical trials focused on racial/ethnic minorities,
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a proportion significantly lower than their percentage
of the US population (36.3%) [6]. Despite the disparities, racial and ethnic minorities, particularly African
Americans [3, 7–9], are consistently underrepresented
in CCTs. The enrollment fraction (the number of trial
enrollees divided by the estimated US cancer cases) in
clinical trials by race/ethnicity for all cancers was 1.8%
for Whites and 1.3% for African Americans [6].
Racial differences in CCT participation can be attributed to various factors, including but not limited to
socioeconomic status (SES), logistical barriers, perception of, and attitude towards clinical research [1, 10].
Studies have identified several reasons for lower clinical
trial participation among minority populations, including distrust of health care institutions, fear of experimentation, lack of awareness of trials and how to find
them, limited representation of minority investigators,
and poor communication with physicians [7, 11]. Based
on a systematic review of the related literature, one of
the most cited conceptual models (Ford Model) focused
on three critical barriers to recruiting underrepresented cancer patients to CCTs, including awareness,
opportunity, and acceptance [8, 12]. This conceptual
model identified barriers to trial awareness including
lack of education, limited culturally appropriate information, inadequate cancer knowledge, and physician
awareness of trials [8, 9, 12]. Significant barriers for the
opportunity to participate were old age, low SES, racial
and ethnic minority status, study eligibility and exclusion criteria, provider attitudes, limited provider referral, and patient-provider communication regarding
trials [8, 12]. Common barriers to acceptance of trial
enrollment based on the Ford Model included mistrust
of the research, perceived harms of clinical trial participation, time commitment, income, and transportation
[12–14]. Moreover, fatalism, low self-efficacy, and limited social support are also associated with lower participation in CCTs [1, 2, 11].
Racial disparities in CCT participation reflect significant structural barriers many African Americans
have to overcome before their participation rate can be
increased. Poverty and living in under-resourced areas
have made it difficult for African Americans to access
care provided by teaching hospitals where CCTs are usually offered. Meanwhile, the underrepresentation of African American professionals in oncological care [15] also
poses a challenge for delivering culturally sensitive care
to African Americans and alleviating their mistrust in
medical research in light of the painful memories of inappropriately conducted clinical trials such as the Tuskegee
Syphilis Study [16]. Perceived or real experience of racism was identified as an important source of mistrust in
healthcare professionals by African Americans, which is
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closely related to their lack of willingness to participate in
medical research [17].
Previous research has revealed that compared with
White Americans, African Americans were not only
less likely to be aware of clinical trials [7, 18], they were
also less willing to participate in clinical trials [19].
Despite the importance of these findings, one limitation
is that most extant studies were based on data collected
from the general population, not from cancer survivors.
Related evidence is more scarce among cancer survivors
in the Midwest. The present study’s primary objective is
to examine differences in awareness of and willingness to
participate in CCTs among Black and White cancer survivors from Nebraska. A secondary objective is to compare differences in perceptions of CCTs between Black
and White cancer survivors.

Methods
Study setting and study population

This study used the data collected as part of a crosssectional survey entitled “Minority Patient Participation
in Cancer Clinical Trials,” conducted by the Center for
Reducing Health Disparities at the University of Nebraska
Medical Center in Omaha, Nebraska, from 2015 to 2016.
The research team recruited a purposive sample of 176
cancer survivors who lived in Omaha, the largest city in
Nebraska. We limited the sample of this study to 147 participants who self-identified as being White or African
American for our analyses. Other races and multiracial
and multiethnic individuals were excluded (n = 29). Our
working sample consisted of approximately 84% of the
full data set.
The research team distributed anonymous paper-based
surveys at several local hospitals, clinics, community
health centers, and a community event supporting African American female breast cancer survivors. Participants were eligible if they were 19 years or older and were
current cancer patients or survivors. Participation in the
survey was voluntary based on informed consent shared
with potential participants at the beginning of the survey.
The survey was completed by the participant themselves
or with the help of research assistants when needed. All
participants received a $20 gift card for compensating
their time for their participation in the survey. Approvals for the study were obtained from the University of
Nebraska Medical Center Institutional Review Board
(IRB# 722–15-EX) before the initiation of data collection.
Measurements

The research team developed and pilot-tested the survey questionnaire in the team before administering the
survey. The questionnaire included basic demographic
information, current cancer treatment status, awareness,
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and perception of CCT, experience in CCT participation,
access to health services, and psychosocial constructs
on social support, general self-efficacy, fatalism, and
hopefulness.
Outcome variables

The primary outcome variables for our analyses are
awareness of and willingness to participate in a CCT.
Awareness of a CCT was assessed by a yes-no response
to the question, “Have you heard about cancer clinical
trials?” The willingness to participate in cancer clinical
trials was measured by two questions. The first question
“Would you ever participate in a cancer clinical trial?”
was asked among all respondents who were provided
with three options, including yes and no/unsure. The
other question was only asked among those respondents
who indicated that they had been offered to participate
in a CCT, “Did you accept the offer to participate in the
cancer clinical trial?” with three response options including yes, no/unsure.
Participant perception of CCT was based on response
to the following questions: 1) “If your physician recommends that you participate in a cancer clinical trial, do
you trust that he or she would fully explain it to you?”
2) “Do you believe you can freely ask your physician any
questions about cancer clinical trials?” 3) “How often, if
ever, do you think physicians prescribe medication as a
way of experimenting on people without their knowledge or consent?” 4) “What are some of the features you
would expect from a good cancer clinical trial program?”
5) “I have a good understanding about how clinical trials
work” (strongly agree, agree, neutral, disagree, strongly
disagree). 6) “Do you feel like clinical trials make a significant contribution to science (strongly agree, agree, neutral, disagree, strongly disagree)?” While the first three
questions focused on patient trust in physicians, the
fourth question assessed patient preferences for CCTs,
and the final two questions evaluated understanding and
knowledge of CCTs.
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Multidimensional Scale of Perceived Social Support
(MSPSS) This is a 12-item measure of social support’s perceived adequacy from three sources: family,
friends, and significant other using a 5-point Likert scale
(0 = strongly disagree, 5 = strongly agree). Mean score
ranging from 1 to 2.9 suggests low support; a score of 3
to 5 indicates moderate support, and a score from 5.1 to
7 could be considered high support [20]. The Cronbach’s
alpha of MSPSS was 0.96 in the current sample, suggesting very good internal consistency.
Fatalism scale This scale measures cancer fatalism and
comprises of three dimensions: predetermination, luck,
and pessimism. The scale consists of 20 items with an
overall score ranging from 20 to100 based on five-point
Likert scales, with a higher score indicating a higher level
of fatalism. The scale is reliable and valid for measuring
fatalism among cancer patients [21]. Internal consistency
reliability was estimated with Cronbach’s alpha (α) of 0.90
in the current sample.
General Self-Efficacy scale (GSE) This 10-item self–
assessment scale about the general belief in oneself to
solve problems and reach goals. The scale ranges from 10
to 40, with higher scores denoting better self-efficacy or
confidence in your ability to manage an illness or follow
through with behavior change successfully. It has wellestablished validity and reliability [22], and in the present
study, Cronbach’s alpha is 0.89.
Herth Hope index This is a 12 item self-assessment
scale measures various dimensions of hope using a
4-point Likert scale that ranges from 1 (strongly disagree)
to 4 (strongly agree). The scale has one global score that
ranges from 12 to 48, with higher scores associated with
more hope. The scale is valid and reliable [23], and in the
current study, the estimated Cronbach’s alpha was 0.85.

Statistical analysis
Explanatory variables

Demographics, socioeconomic status, and health Basic
demographic information included sex (male, female)
and self-reported race (Whites and African American). Socioeconomic status was characterized by education level (up to high school, some college or more),
marital status (married; non-married), employment status (employed, non-employed), and individual annual
income (≤ $49,999, ≥ $50,000). Indicators on health
included self-rated health status (high, low), physical
activity status (active, non- active), and current cancer
treatment status (yes, no).

We first used descriptive statistics to profile the sample
and to compare demographics and health characteristics between Black and White cancer survivors. Means
and standard deviations were calculated for continuous variables, whereas categorical variables were summarized with frequencies and percentages. Chi-square
tests or Fisher’s exact tests were used to assess differences
between groups for categorical variables, and t-tests were
used to evaluate differences with respect to continuous variables. For multiple response variables, we used
Cochran’s Q test to assess group differences [24]. Multivariable logistic regressions were estimated to examine
racial differences in the odds of being aware of a CCT
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or willing to participate in it after adjusting for relevant
confounders. Two-sided p values of less than 0.05 were
considered statistically significant. The statistical analysis was performed using the IBM Statistical Package for
Social Sciences for Windows, Version 25.0.

Results
Racial differences in selected covariates included in our
analysis are shown in Table 1. Out of the 147 cancer
survivors, 95 (or 65%) were Black, and 52 (or 35%) were
White. There was an obvious gender imbalance in the
sample with 86% being female. Black and White cancer
survivors differed significantly with respect to socioeconomic characteristics. Relative to White cancer survivors, African American cancer survivors were less likely
to be married (41% vs. 71%; p < 0.001) and had a lower
level of education, with 59% having completed some

college or more as compared to 83% among White cancer
survivors (p < 0.001). White cancer survivors had higher
incomes and a higher proportion currently undergoing
cancer treatment. Another notable difference was that
Black cancer survivors showed a higher level of fatalism
compared to White cancer survivors (p = 0.011). The two
racial groups had similar employment status, self-rated
health status, and physical activity levels.
Racial differences in awareness of and willingness
to participate in CCTs

When asked whether they had ever heard about cancer
clinical trials, 63% of the respondents answered positively
(Table 2). Cancer clinical trials’ awareness was much
higher among white cancer survivors than among African Americans (80% vs. 52%), and the difference was statistically significant (p = 0.001).

Table 1 Sample description by race (number (%) or mean (standard deviation))
Variables

Total (n = 147)

White (n = 52)

Black (n = 95)

Male

20 (14)

12(24)

8 (8)

Female

126 (86)

39 (76)

87 (92)

Up to high school

48 (33)

9 (17)

39 (41)

Some college or more

99 (67)

43 (83)

56 (59)

Married

76 (52)

37 (71)

39 (41)

Non-married

71 (48)

15 (29)

56 (59)

Employed

73 (51)

26 (50)

47 (51)

Unemployed

72 (49)

26 (50)

46 (49)

≤ 49,999

101 (71)

30 (58)

71 (79)

≥ 50,000

41 (29)

22 (42)

19 (21)

High

102 (69)

35 (67)

67 (70)

Low

45 (31)

17 (33)

28 (30)

Active

114 (81)

42 (84)

72 (81)

Non-Active

26 (19)

9 (18)

17 (19)

Yes

39 (27)

21 (40)

18 (20)

No

Gender

P-value
0.011

Educational Level

0.003

Marital Status

0.001

Employment Status

0.950

Individual income ($)

0.007

Self-Rated Health Status

0.686

Physical Activity Status

0.831

Current treatment status

0.008
104 (73)

31 (60)

73 (80)

Years survived after initial cancer diagnosis, mean
(S.D.)

10.85 (9.89)

7.05 (7.73)

13.25 (10.39)

0.007

Social Support Scale, mean (SD)

4.16 (0.84)

4.25 (0.67)

4.11 (0.91)

0.318

Fatalism Scale, mean (SD)

2.32 (0.61)

2.18 (0.55)

2.47 (0.67)

0.011

General Self Efficacy Scale, mean (S.D.)

3.21 (0.50)

3.24 (0.43)

3.19 (0.58)

0.579

Herth Hope Index, mean (SD)

3.12 (0.49)

3.09 (0.44)

3.16 (0.55)

0.467

Not all columns add up to n = 147 due to missing value. Chi-square tests or Fisher’s exact tests were conducted for categorical variables, and t-tests were used for
continuous variables
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Table 2 Awareness of and Willingness to Participate in CCT by Race
Variables

Total n (%)

White n (%)

Black n (%)

Yes

85 (62.5)

40 (80.0)

45 (52.3)

No

51 (37.5)

10 (20.0)

41 (47.7)

Yes

59 (42.1)

35 (68.6)

24 (27.0)

No/Unsure

81 (57.9)

16 (31.4)

65 (73.0)

Yes

25 (30.5)

15 (57.7)

10 (16.9)

No/Unsure

60 (69.5)

11 (42.3)

49 (83.1)

Have you heard about CCT?

P- value
0.001

Would you ever participate in CCT?

< 0.001

Did you accept the offer to participate in CCT?

< 0.001

P values were based on Chi-square tests of the bivariate associations between race and selected variables

When asked whether they would be willing to participate in a CCT, overall, 42% of the respondents were
willing, and 58% were unsure or were not interested in
participation. However, there were significant differences
in willingness to participate between Black and White
cancer survivors. Sixty-nine percent of White cancer survivors were willing to participate in a CCT, as compared
to 31% of African Americans (p < 0.001). Among all
respondents who reported that they had been offered the
opportunity to participate in a CCT, 31% reported that
they accepted the offer to participate. This percentage
of ever participated in a CCT was much higher among
White cancer survivors (58%) than among Black cancer
survivors (17%) (p < 0.001).
Table 3 displays the adjusted odds ratios (AOR) of significant factors associated with awareness of and willingness to participate in cancer clinical trials. After adjusting
for the effect of selected variables on demographics, socioeconomic status, self-rated health, physical activity status, current cancer treatment status, and psychosocial
characteristics, Black cancer survivors were much less
likely than White cancer survivors to be aware of a CCT
(AOR 0.26; CI 0.08–0.81), to express willingness to participate in a CCT (AOR 0.13; CI 0.04–0.38), and to actually accept the offer to participate in a CCT (AOR 0.03;
CI 0.01–0.32).

Racial differences in perception of cancer clinical trials

When asked, “If your physician recommends that you
participate in a cancer clinical trial, do you trust that he
or she would fully explain it to you?”, 96% of White cancer
survivors and 86% of African American cancer survivors
in the study responded yes (p = 0.06) (Table 4). In both
groups, over 90% thought they could freely ask physicians
any questions about the cancer clinical trials (p = 0.71).
However, an important difference between the two
groups lies in their responses to the question “How often,
if ever, do you think physicians prescribe medication as a
way of experimenting on people without their knowledge
or consent?” While 34% of African American cancer survivors believed this was done very or fairly often, only 6%
of the White cancer survivors believed this was the case
(p < 0.001).
The two groups of cancer survivors also showed differences in their preferences of desired features of a good
cancer clinical trial program. The most preferred feature
for African Americans was that the program could send
the trial’s educational information through mails, followed by having the trial close to residence. By contrast,
the most preferred feature for White cancer survivors
was providing online information about the program,
followed by flexible scheduling and sending educational
information about the trial through mails.

Table 3 Logistic regressions on awareness of and willingness to participate in CCT among White and Black cancer survivors (adjusted
odds ratio & 95% confidence interval)
Race

Awareness of CCT

Expressed Willingness to Participate in
CCT

Actual Participation in CCT

White

1.00

1.00

1.00

Black

0.26* (0.08, 0.81)

0.13** (0.04, 0.38)

0.03** (0.01, 0.32)

Adjusted odds ratios associated with race were estimated after controlling for the effect of gender, educational level, marital status, employment status, individual
income, self-rated health status, physical activity status, current status of treatment, years survived after initial cancer diagnosis, social support, fatalism, general selfefficacy and hope index
*

p < 0.05

**

p < 0.01
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Table 4 Perception of CCT by race
Survey Questions

Total n (%) White n (%) Black n (%) P-value

If your physician recommends that you participate in a cancer clinical trial, do you trust that he or
she would fully explain it to you?

0.06

Yes

122 (90)

48 (96)

74 (86)

No

14 (10)

2 (4)

12 (14)

Yes

127 (94)

48 (96)

79 (93)

No

8 (6)

2 (4)

6 (7)

Do you believe you can freely ask your physician any questions about cancer clinical trials?a

0.710

How often, if ever, do you think physicians prescribe medication as a way of experimenting on
people without their knowledge or consent?

0.001

Very/ Fairly often

33 (24)

3 (6)

30 (34)

Rarely/Never

67 (49)

34 (69)

33 (38)

Do not know

26 (27)

12 (25)

24 (28)

What are some of the features you would expect from a good cancer clinical trial program (select
all that apply)?a

0.001

Send me the educational information through mails

99 (74)

39 (29)

60 (45)

Online information about the program

73 (55)

41 (31)

32 (24)

Offer flexible scheduling

84 (63)

39 (29)

45 (34)

Close to where I live

85 (63)

32 (24)

53 (40)

A physician with a similar cultural background as me

32 (24)

6 (5)

26 (19)

Communication technology including telemedicine

65 (49)

28 (21)

37 (28)

Others

12 (9)

6 (5)

6 (5)

44 (33)

11 (22)

33 (39)

I have a good understanding about how clinical trials work.
Strongly disagree/Disagree

0.090

Neutral

42 (31)

16 (32)

26 (30)

Strongly Agree/Agree

49 (36)

23 (46)

26 (30)

13 (10)

2 (4)

11 (13)

Do you feel like clinical trials make a significant contribution to science?
Strongly disagree/Disagree

a

0.015

Neutral

25 (19)

5 (10)

20 (24)

Strongly Agree/Agree

95 (71)

43 (86)

52 (63)

Multiple response variable and Cochran’s Q p value used

In terms of understanding and knowledge of CCTs,
46% of Whites and 30% of African Americans in the sample believed that they had a good understanding of how
clinical trials worked (p = 0.09). However, a more pronounced difference between the two groups was their
opinion on whether clinical trials make a significant contribution to science. Eighty-six percent of White cancer
survivors believed that clinical trials make a substantial
contribution to science, as compared to 63% among African American cancer survivors (p = 0.015).

Discussion
The underrepresentation of African American patients
in CCTs remains a challenge for developing personalized, precision medicine in cancer therapy. According to the U.S. Federal Drug Administration, out of the
5157 patients who participated in clinical trials that led
to the approvals of 17 new cancer drugs in 2018, only 4%
of them were African American patients [25]. Based on

survey data collected from cancer survivors in Nebraska,
our findings in the current study point to several significant barriers that have hindered CCT participation
among African American cancer patients, including lack
of awareness of CCTs, lack of willingness to participate in
CCTs, distrust in physicians, and prevailing misconceptions of CCTs.
Being aware of clinical trials is necessary for cancer
patients to make informed decisions on trial participation. The substantial gap in CCT awareness between
White and African American cancer survivors, as
revealed in this study (80% vs. 52%), underscores the
need to identify unique barriers encountered by African American cancer patients in knowing about CCTs.
While part of these barriers might be related to the relatively lower level of education and health literacy among
African Americans, our study’s findings suggested that
adjusting for the effect of education and other socioeconomic status variables did not substantially alter the
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originally observed racial gap in CCT awareness. Multiple studies have shown that African Americans have a
general lack of grasp of the research process and medical terms like clinical trials and medical research [26,
27]. A study that looked at cancer health literacy among
African Americans, Whites, and Hispanics backed with
similar findings. On a cancer health literacy test, African
American participants scored much lower than white
participants [28]. The relatively lower level of health literacy among African Americans could lead to problems in
understanding the informed consent process in biomedical research, a common obstacle to African American
involvement in CCT [27, 29]. Another qualitative study
interviewing African American cancer survivors at a
safety-net hospital identified that a lack of understanding
of cancer clinical trials was one of the major barriers of
participation in cancer trials [28, 30]. The study reported
that many survivors were confused and even could not
be differentiated between a cancer clinical trial and treatment of cancer [31]. Our findings are consistent with
these studies and suggest the need to provide culturally
and linguistically appropriate cancer clinical trial information to AA cancer survivors to ensure understanding
of important clinical trial terms and concepts. Some of
the evidence-based strategies include a culturally tailored educational video or in-person education [32, 33],
patient-focused, relationship-building communication
strategies [34], or the use of patient navigators [35].
Since physicians are the primary source of information for patients to know about CCTs [36–38], it would
be also important to examine CCT awareness among
care providers serving African American patients and
whether these care providers would inform African
American patients about CCTs. There was evidence that
oncologists’ visits with African American patients, on
average, were shorter compared with visits with White
patients and included less discussion of the purpose and
risks of trials offered but more discussion of voluntary
participation. As a result, African American patients may
make decisions about clinical trial participation based on
less discussion with oncologists than do White patients
[37–39].
Besides limited awareness of cancer trials, Black cancer survivors also demonstrated much less willingness
to participate in the trials. Among the 57 Black cancer
survivors in this study who had been offered to participate in a CCT, only 10 of them, or 18%, accepted the offer
compared to 60% among White cancer survivors. Closely
related to the lower participation rate in Black cancer
survivors were the observation that, relative to White
cancer survivors, Black cancer survivors reported a
higher level of distrust in physicians and misconceptions
of CCTs. Previous studies also documented that Black
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cancer patients were more likely than their White counterparts to express distrust in CCTs [39, 40]. Besides the
trust issue, the knowledge gap in understanding CCTs
between the two racial groups should also be addressed
to encourage CCT participation among African American cancer survivors. Cancer patients are usually more
likely to participate in CCTs when they are convinced
of the treatment efficacy or how the trial results could
advance cancer treatments and benefit other patients.
According to findings from one recent study [40], the top
two reasons patients cited for their participation in CCTs
were 1) ‘the trial offered the best treatment available’ and
2) that ‘the trial results could benefit others.’ This study
concluded that patients’ motivations for trial participation included perceived personal benefit and altruistic
reasons. Effective and culturally appropriate communication between care providers and African American cancer patients is important and needed to reduce distrust
and improve patient understanding of clinical trials
[41, 42]. Studies on perceptions of clinical trials among
racial and ethnic minorities have consistently shown the
importance of developing culturally specific assessments
for these perceptions and tailoring educational strategies
to correct misconceptions [19, 43–46].
Moreover, our study findings showed a higher level
of fatalism and hopefulness, lower self-efficacy, and
social support among African Americans when compared to White Cancer survivors. This difference could
be explained by the substantial gap in African American
participants’ socio-demographic characteristics such
as gender, educational level, marital status, and income
compared with Whites. These factors could also influence
the racial differences in awareness of and willingness to
participate in the CCT in the given sample. Studies have
suggested that cancer fear, cancer fatalism, along with
limited social support, and self-efficacy have a direct or
indirect influence on the cancer care continuum, awareness of and willingness to participate in CCTs [2, 39, 42].
This study provides some clues on designing future
CCTs that might appeal to African American cancer
patients. The top three desired features of CCTs identified by African American cancer patients in the study
included sending information about the trial through
mails, having the trial close to residence, and offering
flexible scheduling for participation, which were somewhat different from the features preferred by White cancer survivors in the study. Meanwhile, African American
cancer survivors were more likely than White cancer survivors to prefer having a physician with a similar cultural
background (19% vs. 5%). There was also evidence that
relative to Whites, African Americans were more likely
to look to their churches for clinical trial information,
whereas Whites were more likely to seek information
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from a doctor or the Internet [19]. These differences
between the two racial groups reinforce the need to
develop tailored strategies for recruiting diverse groups
of cancer patients into clinical trials. Enrolling individuals with specific cultural backgrounds and literacy
levels may help to increase the recruitment of underrepresented groups (African Americans). Patient navigation
models, which involve delivering educational and facilitative services to patients, have been proposed to promote
the retention of African Americans in cancer clinical trials, with one study indicating a 9 to 16% increase in participation [45]. Attempts to lessen the influence of bias in
clinical interactions could be another answer. Training
healthcare providers in the use of high-quality patientcentered communication are one possibility. Health care
providers must be culturally aware and exhibit proper
communication skills in order to successfully enroll
African Americans in clinical trials [44, 45]. Additionally, leveraging a community’s resources and assets while
conducting collaborative research and building equitable
partnerships has the potential to strengthen community
buy-in and engagement in CCT [46].
Study limitations and strengths

Several limitations of our study are noteworthy in light
of the results. First, the cross-sectional design, in conjunction with our reliance on self-report of clinical trial
participation, can lead to potential recall bias. Secondly,
our use of a convenience sample in Nebraska with oversampling of African American cancer survivors calls for
caution when generalizing findings from the study to
other cancer survivor populations. In particular, our success in recruiting many African American breast cancer
survivors from a major annual event hosted by My Sister’s Keeper, our community partner in this study, has
resulted in the overrepresentation of females and African
American breast cancer survivors in this study. Future
studies can assess the robustness of our findings in more
representative samples of cancer survivors. Thirdly, some
measures used in this study such as awareness of CCTs,
willingness to participate in CCTs, and trust in physicians, were developed by the study team, not based on
extant, validated measures from the literature. Their
validity and reliability need to be further assessed before
being adopted in other studies. Finally, due to data constraints, patient perception of CCTs was based on the
analysis of multiple-choice questions in the survey, not
qualitative feedback from patients, which has limited the
depth of the analysis. Despite these limitations, to our
knowledge, the study represents a rare effort that has
revealed substantial gaps in awareness of and willingness
to participate in CCTs between White and Black cancer
survivors in the Midwest with a large rural population,
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and related racial differences in the perceptions of clinical
trials and trust in physicians. The identified differences in
the desired features of clinical trials between Black and
White cancer survivors in this study might help facilitate
the development of future clinical trials that can more
effectively engage cancer patients.

Conclusions
Relative to White cancer survivors, African American
cancer survivors were much less likely to be aware of or
to participate in CCTs. These disparities persisted with
or without adjusting for racial differences in demographics, SES, health status, psychosocial status (hopefulness,
fatalism, self-efficacy), and other factors considered in
this study. Consistent with these disparities, African
American cancer survivors reported a lower level of
trust in physicians and a more deficient understanding
of CCTs. Developing tailored, evidence-based strategies
to more effectively engage African American cancer survivors and increase their awareness of and willingness to
participate in CCTs would be crucial for improving the
representativeness of minority patients in CCTs and for
addressing racial disparities in CCT participation.
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